Importer of Controlled Substances; Notice of Application, 75494-75495 [2010-30344]
Download as PDF
<![CDATA[
75494
Federal Register / Vol. 75, No. 232 / Friday, December 3, 2010 / Notices
Onondaga County
Shepard Settlement Cemetery, Stump &
Foster Rds, Shepard Settlement, 10000938
Orange County
Beakes, John G., House, 134 W Main St,
Middletown, 10000939
Grace Episcopal Church, 58 N St,
Middletown, 10000945
Mapes, Mortimer L., House & Seward
Homestead, 35 N Main St, Florida,
10000942
TEXAS
Drug
Harris County
Near Northside Historic District, Roughly
bounded by Little White Oak Bayou on the
N; Hogan on the S; I–45 On the W and the
block between N Main and Keene Houston,
10000960
Hays County
Lane, James C., House, (Rural Properties of
Hays County, Texas MPS) 306 Wimberley
Square, Wimberley, 10000961
St. Lawrence County
Fort la Presentation Site, Address Restricted,
Ogdensburg, 10000944
Hunt County
Washington Hotel, 2612 Washington St,
Greenville, 10000962
Steuben County
Gold Seal Winery, West Lake Rd,
Hammondsport, 10000946
Uvalde County
Nicolas Street School, 332 Nicolas St,
Uvalde, 10000963
Sullivan County
Greenfield Preparative Meeting House, NY 55
at Denman Mt Rd, Grahamsville, 10000956
Related Action: Request for REMOVAL has
been made for the following resources:
Washington County
McNish, Alexander, House, 194 CR 30, New
York, 10000959
Simonds, L.C., Adirondack Cabin, 130 Cat
Den Rd, Clemons, 10000941
Larimer County
Big Thompson River Bridge I, US 34 at
milepost 65.53 Larimer, 02001144
Big Thompson River Bridge II, US 34 at
milepost 66.22 Larimer, 02001141
SOUTH DAKOTA
Brookings County
Hall, John L., House, 121 Samara Ave, Volga,
10000955
Lockhart House, 1001 6th Ave, Brookings,
10000954
Davison County
Henline, Ellis and Roberta Farmstead, 39987
252nd St, Mount Vernon, 10000950
Faulk County
Edgerton, Dr. William, House, 308 Tenth Ave
S, Faulkton, 10000951
Tripp County
Wewela Hall, Lots 3 and 4, Block 34,
Government Townsite of Wewela, Wewela,
10000952
Walworth County
Molstad Lake Park, (Federal Relief
Construction in South Dakota MPS) 1 3⁄4 mi
N of HWY 12 on 293rd Ave, Glenham,
10000953
TENNESSEE
Anderson County
Daugherty Furniture Building, 307 N Main
St, Clinton, 10000936
mstockstill on DSKH9S0YB1PROD with NOTICES
Davidson County
Municipal Public Works Garage Industrial
District, 33 Peabody St, Nashville,
10000949
Henderson County
Doe Creek School, Doe Creek Rd, approx 1⁄2
mi N of Dyer Rd, Sardis, 10000935
Knox County
Lebanon in the Forks Cemetery, (Knoxville
and Knox County MPS) Asbury Rd N of
Norfolk Southern Railroad, Knoxville,
10000934
VerDate Mar<15>2010
16:09 Dec 02, 2010
Jkt 223001
COLORADO
KENTUCKY
Jefferson County
Bloedner, August, Monument, Cave Hill
Cemetery, jct. of Payne St. & Lexington Rd.,
Louisville, 97000688
[FR Doc. 2010–30312 Filed 12–2–10; 8:45 am]
BILLING CODE 4312–51–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on October
6, 2010, Mylan Technologies, Inc., 110
Lake Street, Saint Albans, Vermont
05478, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in schedule II:
Drug
Schedule
Methylphenidate (1724) ................
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
II
Fentanyl (9801) ............................
Schedule
II
The company plans to import the
listed controlled substances in finished
dosage form (FDF) from foreign sources
for analytical testing and clinical trials
in which the foreign FDF will be
compared to the company’s own
domestically-manufactured FDF. This
analysis is required to allow the
company to export domesticallymanufactured FDF to foreign markets.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration,
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 3, 2011.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: November 19, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–30336 Filed 12–2–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
E:\FR\FM\03DEN1.SGM
03DEN1
mstockstill on DSKH9S0YB1PROD with NOTICES
Federal Register / Vol. 75, No. 232 / Friday, December 3, 2010 / Notices
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on June 4,
2010, Clinical Supplies Management,
Inc., 342 42nd Street South, Fargo,
North Dakota 58103, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Sufentanil (9740), a basic
class of controlled substance listed in
schedule II.
The company plans to import the
listed controlled substance with the sole
purpose of packaging, labeling, and
distributing to customers which are
qualified clinical sites conducting
clinical trials under the auspices of an
FDA-approved clinical study.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration,
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 3, 2011. This
procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
VerDate Mar<15>2010
16:09 Dec 02, 2010
Jkt 223001
Dated: November 18, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–30344 Filed 12–2–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on July 28,
2010, Fisher Clinical Services, Inc.,
7554 Schantz Road, Allentown,
Pennsylvania 18106, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in schedule
II:
Drug
Schedule
Noroxymorphone (9668) ..............
Tapentadol (9780) ........................
II
II
The company plans to import the
listed substances for analytical research
and clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration, and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 3, 2011.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
75495
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: November 18, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–30348 Filed 12–2–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on
September 13, 2010, Chattem
Chemicals, Inc., 3801 St. Elmo Avenue,
Building 18, Chattanooga, Tennessee
37409, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
4-Anilino-N-Phenethyl-4-Piperidine
(ANPP) (8333), a basic class of
controlled substance listed in schedule
II.
The company plans to import this
controlled substance in bulk for use in
the manufacture of another controlled
substance.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration,
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
E:\FR\FM\03DEN1.SGM
03DEN1
]]>Agencies
[Federal Register Volume 75, Number 232 (Friday, December 3, 2010)]
[Notices]
[Pages 75494-75495]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-30344]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing
[[Page 75495]]
a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on June 4, 2010, Clinical Supplies Management, Inc., 342 42nd
Street South, Fargo, North Dakota 58103, made application by renewal to
the Drug Enforcement Administration (DEA) to be registered as an
importer of Sufentanil (9740), a basic class of controlled substance
listed in schedule II.
The company plans to import the listed controlled substance with
the sole purpose of packaging, labeling, and distributing to customers
which are qualified clinical sites conducting clinical trials under the
auspices of an FDA-approved clinical study.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration, and may, at the same time, file a written
request for a hearing on such application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than January 3, 2011. This procedure is to be conducted
simultaneously with, and independent of, the procedures described in 21
CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice
published in the Federal Register on September 23, 1975, (40 FR 43745-
46), all applicants for registration to import a basic class of any
controlled substance in schedule I or II are, and will continue to be,
required to demonstrate to the Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement Administration, that the
requirements for such registration pursuant to 21 U.S.C. 958(a); 21
U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: November 18, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-30344 Filed 12-2-10; 8:45 am]
BILLING CODE 4410-09-P
